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include the bilateral mediastinal nodal re-
gions independently by their involvement.
New data from RTOG trials4 suggest mov-
ing the elective nodal irradiation focalizing
to the gross tumor volume. In our recent
published report,5 exploring a combined
modality treatment with limited irradiation
volume, we have reported a grade 3 esoph-
ageal toxicity rate of 1.1%.
Moreover, surgical-related mortality, as
the authors stated, could be attributed to the
type of operation, pneumonectomy, more
than to induction protocol. Also, data from
neoadjuvant chemotherapy support these
findings.6
Today, lymph node clearance7 and
pathologic downstaging have been pro-
posed as surrogate endpoints for neoadju-
vant treatment in LA-NSCLC. Data from
SAKK and the University of Pennsylvania
agree to group together pathologic stage I
and II (or pN0-1) disease as a predictor of
overall survival and event-free or local re-
currence-free survival. If we look at the
Memorial Sloan Kettering data on 470 pa-
tients treated with neoadjuvant therapy,8
the multivariate analysis shows us a statis-
tically significant difference in term of the
relative rate of deaths between pathologic
stage 0 and stage II to IV disease. No
differences have been reported between
pathologic stage 0 and stage I disease. Ac-
cording to this and our analysis, we share
the hypothesis to use pathologic downstag-
ing to stage 0 to stage I as a direct indicator
of the effectiveness of any multimodality
approach to LA-NSCLC.
Finally, 2 more issues regarding patho-
logic downstaging have to be underlined:
its value as a predictor of distant recurrence
and disease-free survival. In our analysis
we have found a direct effect of downstag-
ing on these parameters that stress the im-
portance of local control on lung cancer,
generally considered a systemic disease,
and the ability of surgical intervention to
achieve an eradication of lung carcinoma.
This last consideration could directly
affect the quality of life of patients accord-
ing to the following syllogism: “no cancer,
no treatment; no treatment, no side ef-
fect”—and no doctors, too.
Rolando M. D’Angelillo, MD
Lucio Trodella, MD
Sara Ramella, MD
Department of Radiotherapy
Università Cattolica S. Cuore
Rome, Italy
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Studying the lumen in composite Y
internal thoracic artery–saphenous
vein grafts
To the Editor:
We congratulate Gaudino and colleagues1
for the splendid idea advanced in their
study on composite Y internal thoracic ar-
tery (ITA)–saphenous vein (SV) grafts.
The study of the lumen contributes enor-
mously to the current series of studies de-
scribing the characteristics of composite
grafts. However, we do not share some of
the opinions presented in this article. We
believe that it is not right to use the term
“flow steal” in this specific case, because
the circulatory system is pressurized, is
closed, and responds well to demand. We
do not agree that SV grafts are the worst
conduits. It is already known that SVs in
aorta–left anterior descending coronary ar-
tery grafts are patent in 70% to 80% of the
patients after 10 years. We also believe that
the reduced diameter in distal ITA used to
revascularize coronary arteries that have a
proximal moderate stenosis (70%) is
physiologic and expected. The distal ITA
lumen may be reduced as well when the
supplied coronary artery has a poor runoff.
If there is no flow demand, the ITA graft
will decrease in caliber, because ITA has a
huge ability to adapt itself to flow demand.
It is commonly seen that an ITA supplying
coronaries with proximal severe stenosis
and a good runoff is usually dilated.2 The
fact that SV is less reactive does not com-
promise the coronary irrigation to which it
is anastomosed, because the blood flow in
SV is proportional to the coronary runoff
and not to its diameter. Nevertheless, we
agree with current studies that demonstrate
ITA’s capacity to adapt to flow demand.3
We strongly believe that SV segments do
not jeopardize the composite graft effi-
ciency and have several advantages when
used in such configuration: they are
smaller, they suffer less pressure and shear
stress, and they receive substances pro-
duced by ITA’s endothelium (nitrous ox-
ide, for example). These advantages are
believed to increase SV graft durability.4-6
One must also question results from an
experiment that did not use a group control;
in addition, the small sample does not al-
low for definite conclusions, indicating the
need for more research in this area.
José Glauco Lobo Filho, MD, MM, PhD
Maria Claudia de Azevedo Leitão, MD
Antonio Jorge de Vasconcelos Forte
ICORP
Clinical Research
Fortaleza, Brazil
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Reply to the Editor:
We thank Filho and colleagues for their
comments. Although the capacity of the
internal thoracic artery (ITA) to adapt its
caliber to the flow demand is well known,
in our series of composite Y ITA–saphe-
nous vein (SV) grafts the proportion of
cases with clear graft malfunction (string or
occlusion) that resulted in ischemia in the
grafted territory was not negligible. Re-
versibility of the string sign has been anec-
dotally reported but cannot be accepted for
sure, and in our series it was shown to be
unlikely by the scintigraphic evidence of
inducible ischemia. For these reasons the
term “flow steal” and our word of caution
regarding the adoption of these type of
hybrid grafts seem substantiated.
The hypothesis that SV graft durability
can be increased by the vasoactive sub-
stances produced in the proximal tract of
the ITA is totally speculative and requires
objective investigation before consider-
ation. Moreover, the fact that the SV is
usually anastomosed to the extreme proxi-
mal tract of the ITA minimizes the amount
of ITA-produced substances to which the
SV graft is exposed.
Finally, because this type of graft con-
figuration is used at our institution only in
complex technical cases as last resort, re-
cruitment of a control group would have
been ethically unacceptable.
Mario Gaudino, MD
Gianfederico Possati, MD
Department of Cardiac Surgery
Catholic University
Rome, Italy
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